Polyrizon
Innovative Intranasal Products
Startup Public Health Tech & Life Sciences Est. 2020
Total Raised
$23.53M
Public
Last Round
$17M
8 rounds
Investors
2
2 public
Team
4
1-10 employees
Confidence
90/100
News
45
articles
Patents
1
About
Polyrizon is a biotech company focused on the development and commercialization of innovative intranasal products. Polyrizons Capture & Contain (C&C) platform is based on a natural 3D polymeric network tailored to optimally adhere to the nasal mucosal surface. The polymeric network creates a physical barrier that captures and contains biological contaminants, preventing their penetration. The C&C platform can be readily adapted for a wide range of applications to protect the human body from airborne contaminants such as allergens, viruses, and molds. The companys Trap & Target (T&T) platform delivery technology is designed to allow a long residence time and intimate contact with the mucosal tissue for highly effective targeted delivery of medicines. It can be tailored to address the specific requirements of different molecules for improved therapeutic effect.
Classification
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrug Delivery
Target Customer
Healthcare & Life SciencesMedical Devices IndustryMedical ProductsHealthcareProvidersPatientsLife SciencesPharmaceuticals
Business Model
B2B2C
Tags
allergybiopharmaceuticalbiotechnologypharmaceuticalsbiomaterialspolymerstopical-treatmentpharma-companies
Funding & Events
Oct 2024
Exit Undisclosed
Nov 2020
Undisclosed Round $150K
Xylo Technologies, srugo Reuven construction co. ltd.
May 2022
Seed $718K
srugo Reuven construction co. ltd., Xylo Technologies
Mar 2025
PIPE $17M
Mar 2020
Undisclosed Round $100K
Xylo Technologies
Jun 2023
Seed $400K
srugo Reuven construction co. ltd., Xylo Technologies
Jan 2023
Seed $180K
Xylo Technologies, srugo Reuven construction co. ltd.
Aug 2021
Seed $780K
Xylo Technologies, srugo Reuven construction co. ltd.
News (45)
Oct 6, 2025 · finance.yahoo.com
growth-positive
Polyrizon Announces Positive Pre-Clinical Results: PL-14 Demonstrates Encouraging Allergen-Blocking Efficacy
Product Stage
Sep 19, 2025 · finance.yahoo.com
growth-positive
Polyrizon Submits Pre-Sub Package to the FDA for PL-14 Allergy Blocker
Product Stage
Sep 12, 2025 · finance.yahoo.com
growth-positive
Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study
Product Stage
Aug 14, 2025 · finance.yahoo.com
growth-positive
Polyrizon Regains Compliance with Nasdaq Listing Requirements
Jul 22, 2025 · finance.yahoo.com
growth-positive
Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study
Product Stage
Jul 22, 2025 · finance.yahoo.com
growth-negative
BC-Most Active Stocks
Jul 15, 2025 · finance.yahoo.com
growth-positive
Polyrizon Retains Nasdaq Listing Following Hearings Panel
PIPE/PO
Jun 12, 2025 · finance.yahoo.com
growth-positive
Polyrizon Reports Promising Results Demonstrating Successful Internasal Delivery of its Innovative Hydrogel Formulation for CNS Therapeutics
Product Stage
May 23, 2025 · finance.yahoo.com
growth-negative
Polyrizon Announces Receipt of Nasdaq Delisting Notice
Public Trading
May 21, 2025 · finance.yahoo.com
growth-positive
Polyrizon Emerges with Positive Preclinical Data on Nasal Protection Platform
Product Stage
May 13, 2025 · finance.yahoo.com
growth-positive
Polyrizon Targets $3.15B Epilepsy Market with Preclinical Studies for Innovative Rescue Treatment
Product Stage
May 2, 2025 · finance.yahoo.com
growth-positive
Top Midday Gainers
Public Trading
Apr 25, 2025 · finance.yahoo.com
growth-positive
Polyrizon Reports Successful Safety Study of a Formulation of PL-14 Allergy Blocker in Human Nasal Tissue Model
Product StageFDA approved/pending approval
Apr 11, 2025 · finance.yahoo.com
growth-negative
Polyrizon Receives Nasdaq Notification Regarding Minimum Bid Requirements
Apr 2, 2025 · finance.yahoo.com
growth-positive
Polyrizon Engages Leading Branding Firm for Strategic Brand Development
PartnersProduct Stage
Apr 1, 2025 · finance.yahoo.com
growth-positive
Polyrizon Ltd. Announces Closing of $17.0 Million Private Placement
Investment
Mar 31, 2025 · finance.yahoo.com
growth-positive
Polyrizon Ltd. Announces $17.0 Million Private Placement
Investment
Mar 27, 2025 · finance.yahoo.com
growth-positive
Polyrizon Structures Clinical Strategy for its Allergy Blocker Ahead of FDA Pre-Submission Meeting
Product Stage
Mar 25, 2025 · finance.yahoo.com
growth-positive
Polyrizon Expands Drug Delivery Innovation with Preclinical Studies for Epilepsy Rescue Treatment
Product StagePartners
Mar 21, 2025 · finance.yahoo.com
growth-negative
Psychedelic: atai Life Sciences, NRx report quarterly results
InvestmentProduct Stage
+ 25 more articles
Details
Product Stage
R&D
Employees
1-10
Exact Count
8
District
Center District
Founded
2020
Registrar
513637025
Locations
HaTidhar St 5, Ra'anana, Israel
Links
Admin
Last Update
Oct 6, 2025
Verified by
Natalia Golczar
Claimed
Yes
Missing
markets, not claimed
Team (4)
Tomer Izraeli
Founder & CEO
Founder
Nir Ben Yosef
CFO
Tidhar Turgeman
CRO
Daphna Avital
Chief People Officer